Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note
06:50pm, Tuesday, 25'th Feb 2025
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $166.09, denoting a +1.44% change from the preceding trading day.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Intra-Cellul
J&J sues Samsung Bioepis over contract breach for Stelara biosimilar
05:33pm, Monday, 24'th Feb 2025
Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the drugmaker over the launch of a biosimilar to Stelara, J&J's autoimmune dru
2 Very Healthy High-Yield Dividend Stocks to Buy for a Safe and Growing Passive Income Stream
07:30am, Monday, 24'th Feb 2025
A higher dividend yield is nice because it allows you to collect more dividend income on every dollar you invest in a stock. However, the company paying that dividend needs to be healthy to ensure it
Final Trade: TEVA, JNJ, TJX, BABA
06:27pm, Friday, 21'st Feb 2025
The final trades of the day with the Fast Money traders.
Johnson & Johnson (JNJ) Up 8.9% Since Last Earnings Report: Can It Continue?
12:35pm, Friday, 21'st Feb 2025
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
Phase 3 ASTRO study achieves primary and all secondary endpoints at Week 12 in ulcerative colitis patients The only SC induction data for an IL-23 inhibitor show statistically significant and clinical
Teva Pharma and Alvotech launch US biosimilar to J&J's Stelara
06:44am, Friday, 21'st Feb 2025
Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States.
Johnson & Johnson (JNJ) Laps the Stock Market: Here's Why
06:51pm, Wednesday, 19'th Feb 2025
The latest trading day saw Johnson & Johnson (JNJ) settling at $157.89, representing a +1.87% change from its previous close.
AbbVie Vs. Johnson & Johnson: Graham Would Prefer The Consumer Healthcare Giant
12:26pm, Wednesday, 19'th Feb 2025
Since my last analyses on JNJ and ABBV, both have released Q4 earnings. Overall, JNJ showed more pronounced unevenness in its Q4 results, while ABBV's growth story is pretty clear-cut. The goal of thi
Fast Money: CELH, SLV, EEM, JNJ
06:20pm, Tuesday, 18'th Feb 2025
The final trades of the day with CNBC's Dominic Chu and the Fast Money traders.
J&J begins crucial battle over $10 billion baby powder settlement
06:05am, Tuesday, 18'th Feb 2025
Johnson & Johnson faces a critical test on Tuesday over its $10 billion proposal to end litigation alleging that its baby powder caused ovarian cancer, as it tries to convince a judge to sign off on i
Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon
02:25am, Tuesday, 18'th Feb 2025
Genmab reported strong Q4 2024 results, with $897.4 million in revenue, beating expectations and showing 29% Y/Y growth, driven by Darzalex royalties. 2025 revenue guidance was slightly ahead of conse
Johnson & Johnson: Rich History Of Excellence Poised To Endure
02:16am, Tuesday, 18'th Feb 2025
Johnson & Johnson offers a compelling balance of growth, innovation, and shareholder returns. JNJ's robust financials, including a fortress-like balance sheet and consistent dividends, support its abi
J&J Stock Up More Than 6% in a Month: Time to Buy, Sell or Hold?
09:36am, Monday, 17'th Feb 2025
Those who own JNJ stock may stay invested for some time as the company looks optimistic about a better performance in 2025.
